Intravitreal Bevacizumab for Treatment of Refractory Central Serous Choroidoretinopathy

In a clinical case series, 5 patients with not-resolved central serous choroidoretinopathy (CSC) lasting more than 1 year received one intravitreal bevacizumab injection (IVB, 1.25 mg) injection. All patients underwent a through ophthalmic examination 1 day, 1 week, and 1, 2, and 6 months after the injection. Best corrected visual acuity (BCVA) and central macular thickness were compared before and after treatment by optical coherence tomography. Mean BCVA was improved significantly (p = 0.020) from 0.60 ± 0.25 to 0.50 ± 0.18 and 0.29 ± 0.19 logarithm of minimum angle of resolution at 6 and 18 weeks, respectively. Central macular thickness was also decreased significantly (p = 0.010) from 370 ± 65 to 208 ± 23 µm at 4 months. No recurrence was occurred during follow-up. IVB injection may have beneficial effect in the treatment of refractory CSC

TREATMENT OF DIABETIC MACULAR EDEMA - A COMPARISON BETWEEN ARGON AND DYE-LASERS

To compare the efficacy of argon green and dye yellow photocoagulations, 85 eyes of 85 diabetic patients with diffuse macular edema were included in a prospective randomized clinical trial. One year after treatment, visual acuity was unchanged or better in 85.1% of eyes treated with an argon and 89.5% of eyes treated with a dye laser. A reduction of macular edema was accomplished in 67.3% of eyes in the argon-laser group and in 71.1% of eyes in the dye-laser group. No statistically significant differences were observed between the two groups in regard to visual acuity results or the reduction of macular edema

Associated ocular findings in pericentral pigmentary retinopathy

Macular complications occurred in two isolated patients who had pericentral pigmentary retinopathy. One patient demonstrated bilateral bull's-eye maculopathy and a unilateral full-thickness macular hole. Later, she developed central retinal artery occlusion in the fellow eye. The second patient had a rhegmatogenous retinal detachment that was reattached by scleral buckling surgery, but a full-thickness macular hole was found 3 months postoperatively. In both patients, foveal ischemia may have played a role for the development of macular hole, resulting in poor visual prognosis in pericentral pigmentary retinopathy

Early laser photocoagulation treatment as an option in central serous chorioretinopathy

BACKGROUND AND OBJECTIVE: To investigate the effect of early photocoagulation in central serous chorioretinopathy. PATIENTS AND METHODS: In a prospective study, 15 consecutive patients with central serous chorioretinopathy and single leakage points were treated with photocoagulation between 2 days and 8 weeks after onset of symptoms. The main outcome measures were best-corrected visual acuity and metamorphopsias (Amsler grid) at months 1 and 4 compared with baseline. RESULTS: Mean visual acuity improved by 1.53 lines 1 month after treatment. The mean squares involved in the Amsler grid were reduced by 2.07 squares. No relapse occurred during the follow-up period. CONCLUSION: Considering the characteristics of individuals affected by central serous chorioretinopathy, a fast recovery would be advantageous. This study identified early laser photocoagulation in central serous chorioretinopathy as an effective treatment regarding resorption of subretinal fluid, recovery of visual acuity, and improvement of metamorphopsia. Copyright 2009, SLACK Incorporated